1448348-25-1

Basic information

• Product Name: (S)-N-((S)-1-( 2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-N-(3-fluorophenyl)-5-oxomorpholine-3-carboxamide
• Synonyms: (S)-N-((S)-1-( 2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-N-(3-fluorophenyl)-5-oxomorpholine-3-carboxamide
• CAS NO: 1448348-25-1
• Molecular Weight: 495.886
• Mol File: 1448348-25-1.mol

Chemical Properties

• CAS DataBase Reference: (S)-N-((S)-1-( 2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-N-(3-fluorophenyl)-5-oxomorpholine-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-((S)-1-( 2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-N-(3-fluorophenyl)-5-oxomorpholine-3-carboxamide(1448348-25-1)
• EPA Substance Registry System: (S)-N-((S)-1-( 2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-N-(3-fluorophenyl)-5-oxomorpholine-3-carboxamide(1448348-25-1)

Safety Data

• Hazardous Substances Data: 1448348-25-1(Hazardous Substances Data)

Upstream product

• 1029720-19-1 tert-butyl (3,3-difluorocyclobutyl)carbamate 
• 372-19-0 meta-fluoroaniline 
• 1355328-31-2 1,1-difluoro-3-isocyanocyclobutane 
• 1448348-24-0 (S)-5-oxomorpholine-3-carboxylic acid 
• 587-04-2 m-Chlorobenzaldehyde 
• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 

Downstream Products

• 1448346-14-2 (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-N-(3-fluorophenyl)-5-oxo-4-(pyrimidin-2-yl)morpholine-3-carboxamide 
• 1448345-99-0 (S)-N-(1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-N-(3-fluorophenyl)-5-oxo-4-(pyrimidin-2-yl)morpholine-3-carboxamide 

Relevant articles and documents

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.